Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762225 · ClinicalTrials.gov registry record · Phase 1
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
A Phase 1 study, sponsored by Repertoire Immune Medicines.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04762225 is a Phase 1 study that was terminated before completion, run by Repertoire Immune Medicines. The registered enrollment target is 7 participants.
The verdict
NCT04762225, a Phase 1 study, was terminated before completion, sponsored by Repertoire Immune Medicines.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
Interventions
- BIOLOGICAL RPTR-168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2022-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04762225
The ClinicalTrials.gov registry entry for NCT04762225 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repertoire Immune Medicines, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RPTR-168 is the first listed.
NCT04762225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04762225 about?
NCT04762225 is a clinical study titled "RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma". The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
What is the current status of trial NCT04762225?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-05-10. Estimated completion is 2022-10-11.
What interventions are being tested in trial NCT04762225?
The interventions under investigation include: RPTR-168 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04762225?
This trial is sponsored by Repertoire Immune Medicines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.